Type of medical product:
Indications for use:
Preclinical trials in vivo
Indications: Rheumatoid arthritis
This is a recombinant monoclonal antibody-based therapeutic for treatment of rheumatoid arthritis.
Rheumatoid arthritis is a systemic connective tissue disorder with predominant impairments in small joints of erosive-destructive polyarthritis of unknown origin with a complex autoimmune pathogenesis.
The causes of the disease are still unknown . Indirect data, such as elevation in blood leukocyte count and erythrocyte sedimentation rate (ESR) indicates an infection-related origin of the disease. The disease is believed to be associated with infection causing immune disorders in genetically predisposed persons when so called immune complexes (of antibodies, viruses, etc.) are formed. The latter then accumulates in tissues and induces joint damage. The disease is characterized by a high disability rate (70%) that develops relatively early after the disease onset. The main death cause in these patients are infectious complications and renal failure.